SARS-COV2 VIRULENCE REGARDING ALTITUDE ABOVE SEA LEVEL: THE PERUANIAN SIERRA CASE
Main Article Content
Keywords
Abstract
Background: Covid-19 causes respiratory infections ranging from common colds to severe acute respiratory syndrome. It is speculated that altitude has a protective role against infection, since a lower incidence of the illness has been found in those countries that are at altitudes above 2,500 meters above sea level. Objective: To evaluate the factors that influences the virulence of SARS-CoV2 in places with higher altitudes above sea level. Methodology: The research was conceived as a descriptive, retrospective study. A review of the data on the frequency of infection and mortality rates obtained from the information from the Minsa (Health Ministry of Peru) (2020) and the WHO (2020) in different cities was carried out, making comparisons according to their altitude. Results: The number of deaths in the cities of America that are 2000 meters above sea level is quite high, compared to those cities located at more than 2000 meters above sea level. In Peru, we can see that it is a smaller-scale representation about than is observed on the continent, noting that as we ascend in altitude, the number of deaths from the pandemic caused by Covid-19 is lower. Discussion and Conclusion: Altitude seems to play an important role in the virulence of Sars-COv2, which is attributed to the effects of solar radiation, oxygen concentration, humidity, among other climatic factors, which play an important role in the expression of receptors; however more studies are needed to provide it.
Downloads
References
1. Vizcarra-Vizcarra CA. ¿La altura protege frente a la COVID-19?. Rev Soc Peru Med Interna. 2021;34(2): 88-89. https://bit.ly/3DXRYkZ 2. Gebhard C, Regitz-Zagrosek V, Neuhauser H, Morgan R, Klein S. Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences.2020;11(29):1-13. https://bit.ly/3YpD7YP 3. Organización Mundial de la Salud. Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020. Ginebra: Organización Mundial de la Salud; 2020. https://bit.ly/3Ie1F1g 4. Organización Mundial de la Salud. Nuevo coronavirus - República de Corea (procedente de China) Ginebra: Organización Mundial de la Salud; 2020. https://bit.ly/3YqKI9K 5. Organización Mundial de la Salud. Nuevo coronavirus–Tailandia (procedente de China). Ginebra: Organización Mundial de la Salud; 2020. https://bit.ly/3YCDqz5 6. Briggs H. Coronavirus: cómo se estrecha el cerco sobre el pangolín como probable transmisor del patógeno que causa el covid-19: London: BBC; March 27, 2020. https://bbc.in/3Yl8fsw 7. Hung LS.The SARS epidemic in Hong Kong: what lessons have we learned?. J R Soc Med. 2003;96(8):374-8. https://bit.ly/3YqLcN6 8. Maguiña C; Gastelo R, Tequen A. El nuevo Coronavirus y la pandemia del Covid-19. Rev Med Hered. 2020;31:125-131. https://bit.ly/40HrGNH 9. Arias, C., Zubieta, N., & Poma, L. y. Does the Pathogenesis of SARS-CoV-2 Virus Decrease at High-Altitude? National Library of Medicine. Obtenido de Does the Pathogenesis of SARS-CoV-2 Virus Decrease at High-Altitude?.2020. https://bit.ly/3xbCFRW 10. Grupo de Anàlisi Quantitativa Regional (AQR–UB). El efecto de las condiciones meteorológicas en la propagación del Covid - 19 en el territorio Catalán.AQR-COVID-19/#2. Universitat de Barcelona. Barcelona-Spain. (April 18, 2020). https://bit.ly/3YGD8Hp 11. Salamanca-Fernández E, Rodríguez Barran- co M, Sánchez MJ. Influencia de la temperatura ambiental y la contaminación en la transmisión del SARS-CoV-2. Rev Esp Salud Pública.2021; 95: 20. https://bit.ly/3KdTTGj 12. Pabón, C. (5 de mayo de 2020). Covid - 19 tendría menor virulencia a gran altitud. SCI DEV NET Ediciones América Latina y el Caribe. https://bit.ly/3Xe5F6g 13. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med.2020; 46(4):586–90. https://bit.ly/3x9Uwsv 14. Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al.SARS-CoV2:should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID19?.European Heart Journal. 2020;41(19):1801-1803. https://bit.ly/3DV1tkW 15. Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research. Antiviral Res.2013;100(3): 605–14. https://bit.ly/3K0eyxc 16. Zhang R, WuY, Zhao M, Liu C, Zhou L, Shen S, et al. Role of HIF-1_in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol.2009;297:L631–40. https://bit.ly/40IwEd6 17. Stoyanoff TR, Rodríguez JP, Todaro JS, Colavita JP, Torres AM, Aguirre MV. Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury. Biomed Pharmacother.2018;107:1046–55. https://bit.ly/3XpnS0G 18. Zubieta, G. Covid -19 tendría menor virulencia a gran altitud. Ediciones América Latina y el Caribe.2020.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.